MedTrace Logo

Ribociclib and Bicalutamide in AR+ TNBC

NCT03090165 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-01-02

No results posted yet for this study

Summary

This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.

Conditions

Interventions

DRUG

ribociclib

400mg PO

DRUG

ribociclib

600mg PO

DRUG

Bicalutamide

150mg PO

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Big Ten Cancer Research Consortium

    collaborator OTHER

  • University of Wisconsin, Madison

    collaborator OTHER

  • Kari Wisinski

    lead OTHER

Principal Investigators

  • Kari Wisinski, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090165 on ClinicalTrials.gov